US pharma major Eli Lilly (NYSE: LLY) has announced a definitive agreement to acquire SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to ...

Perhaps STC-004 will flop in upcoming clinical trials. But there's something important to highlight about Eli Lilly that this acquisition brings to light. Beyond the weight management market ...

Perhaps STC-004 will flop in upcoming clinical trials. But there's something important to highlight about Eli Lilly that this acquisition brings to light. Beyond the weight management market ...

This strategic move aims to enhance Eli Lilly’s portfolio in pain management, particularly with SiteOne’s Phase 2 ready Nav 1.8 inhibitor, STC-004. Meanwhile, Australia has approved Eli Lilly’s ...

"Lilly is eager to continue the development of STC-004 with the outstanding SiteOne team as part of our efforts to advance novel, addiction-free pain therapies." ...

LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.

The acquisition is a strategic move by Eli Lilly to bolster its portfolio in the pain management sector, positioning itself to compete with companies such as Vertex (NASDAQ: VRTX). SiteOne ...

The acquisition centers on SiteOne’s STC-004, a Phase 2 ready Nav1.8 inhibitor, which is being researched as a potential new treatment for chronic pain. Mark Mintun, Lilly’s group vice president of ...